Is it accurate to classify ALS as a neuromuscular disorder?

References

• Jutel A. Classification, disease, and diagnosis. Perspect Biol Med. 2011;54:189–205.
   PubMed Web of Science ®Google Scholar
• Rajakulendran S, Dua T, Harper M, et al. The classification of neurological disorders in the 11th revision of the International Classification of Diseases (ICD-11). J Neurol Neurosurg Psychiatry. 2014;85:952–953.
   PubMed Web of Science ®Google Scholar
• Shakir R, Rajakulendran S. The 11th revision of the International Classification of Diseases (ICD): the neurological perspective. JAMA Neurol. 2013;70:1353–1354.
   PubMed Web of Science ®Google Scholar
• Morrison BM. Neuromuscular diseases. Semin Neurol. 2016;36:409–418.
   PubMed Web of Science ®Google Scholar
• Turner MR, Hardiman O, Benatar M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013;12:310–322.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, et al. World federation of neurology research group on motor neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–299.
   PubMed Web of Science ®Google Scholar
• van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084–2098.
   PubMed Web of Science ®Google Scholar
• Brown RH Jr., Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017 Jul 13;377(2):162–172. DOI:10.1056/NEJMra1603471
   Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis ALS/Riluzole study group. N Engl J Med. 1994;330:585–591.
   PubMed Web of Science ®Google Scholar
• Smith R, Pioro E, Myers K, et al. Enhanced bulbar function in amyotrophic lateral sclerosis: the nuedexta treatment trial. Neurotherapeutics. 2017;14:762–772.
   PubMed Web of Science ®Google Scholar
• Writing G, Edaravone ALSSG. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–512.
   PubMed Web of Science ®Google Scholar
• Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology. 2009;73:805–811.
   PubMed Web of Science ®Google Scholar
• Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014;10:661–670.
   PubMed Web of Science ®Google Scholar
• de Vries BS, Rustemeijer LMM, Bakker LA, et al. Cognitive and behavioural changes in PLS and PMA: challengingthe concept of restricted phenotypes. J Neurol Neurosurg Psychiatry. 2019;90:141–147.
   PubMed Web of Science ®Google Scholar
• Turner MR, Barohn RJ, Corcia P, et al. Primary lateral sclerosis: consensus diagnostic criteria. J Neurol Neurosurg Psychiatry. 2020;91:373–377.
   PubMed Web of Science ®Google Scholar
• Ludolph A, Drory V, Hardiman O, et al. A revision of the El Escorial criteria - 2015. Amyotroph lateral scler frontotemporal degener 2015; 16: 291–292.
   Google Scholar
• Carvalho MD, Swash M. Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotroph Lateral Scler. 2009;10:53–57.
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130–133.
   PubMed Web of Science ®Google Scholar
• Andersen PM. ALS and FTD: two sides of the same coin? Lancet Neurol. 2013;12:937–938.
   PubMed Web of Science ®Google Scholar
• Seelaar H, Rohrer JD, Pijnenburg YA, et al. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry. 2011;82:476–486.
   PubMed Web of Science ®Google Scholar
• Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–2477.
   PubMed Web of Science ®Google Scholar
• Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–1014.
   PubMed Web of Science ®Google Scholar
• Burrell JR, Halliday GM, Kril JJ, et al. The frontotemporal dementia-motor neuron disease continuum. Lancet. 2016;388:919–931.
   PubMed Web of Science ®Google Scholar
• Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:153–174.
   PubMed Web of Science ®Google Scholar
• Woolley SC, Strong MJ. Frontotemporal dysfunction and dementia in amyotrophic lateral sclerosis. Neurol Clin. 2015;33:787–805.
   PubMed Web of Science ®Google Scholar
• Blauw HM, Barnes CP, van Vught PW, et al. SMN1 gene duplications are associated with sporadic ALS. Neurology. 2012;78:776–780.
   PubMed Web of Science ®Google Scholar
• Tan RH, Guennewig B, Dobson-Stone C, et al. The underacknowledged PPA-ALS: A unique clinicopathologic subtype with strong heritability. Neurology. 2019;92:e1354–e66.
   PubMed Web of Science ®Google Scholar
• Crockford C, Newton J, Lonergan K, et al. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology. 2018;91:e1370–e80.
   PubMed Web of Science ®Google Scholar
• Elamin M, Bede P, Byrne S, et al. Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology. 2013;80:1590–1597.
   PubMed Web of Science ®Google Scholar
• Josephs KA, Parisi JE, Knopman DS, et al. Clinically undetected motor neuron disease in pathologically proven frontotemporal lobar degeneration with motor neuron disease. Arch Neurol. 2006;63:506–512.
   PubMed Web of Science ®Google Scholar
• Burrell JR, Kiernan MC, Vucic S, et al. Motor neuron dysfunction in frontotemporal dementia. Brain. 2011;134:2582–2594.
   PubMed Web of Science ®Google Scholar
• Walhout R, Westeneng HJ, Verstraete E, et al. Cortical thickness in ALS: towards a marker for upper motor neuron involvement. J Neurol Neurosurg Psychiatry. 2015;86:288–294.
   PubMed Web of Science ®Google Scholar
• Westeneng HJ, Walhout R, Straathof M, et al. Widespread structural brain involvement in ALS is not limited to the C9orf72 repeat expansion. J Neurol Neurosurg Psychiatry. 2016;87:1354–1360.
   PubMed Web of Science ®Google Scholar
• Walhout R, Schmidt R, Westeneng HJ, et al. Brain morphologic changes in asymptomatic C9orf72 repeat expansion carriers. Neurology. 2015;85:1780–1788.
   PubMed Web of Science ®Google Scholar
• Nijboer TCW, Nitert B, Westeneng HJ, et al. A case of ALS with posterior cortical atrophy. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:506–510.
   PubMed Web of Science ®Google Scholar
• Westeneng HJ, Verstraete E, Walhout R, et al. Subcortical structures in amyotrophic lateral sclerosis. Neurobiol Aging. 2015;36:1075–1082.
   PubMed Web of Science ®Google Scholar
• Machts J, Loewe K, Kaufmann J, et al. Basal ganglia pathology in ALS is associated with neuropsychological deficits. Neurology. 2015;85:1301–1309.
   PubMed Web of Science ®Google Scholar
• Schmidt R, Verstraete E, de Reus MA, van den Heuvel MP, et al. Correlation between structural and functional connectivity impairment in amyotrophic lateral sclerosis. Hum Brain Mapp. 2014;35:4386–4395.
   PubMed Web of Science ®Google Scholar
• Bede P, Omer T, Finegan E, et al. Connectivity-based characterisation of subcortical grey matter pathology in frontotemporal dementia and ALS: a multimodal neuroimaging study. Brain Imaging Behav. 2018;12:1696–1707.
   PubMed Web of Science ®Google Scholar
• Schmidt R, de Reus MA, Scholtens LH, van den Heuvel MP, et al. Simulating disease propagation across white matter connectome reveals anatomical substrate for neuropathology staging in amyotrophic lateral sclerosis. Neuroimage. 2016;124:762–769.
   PubMed Web of Science ®Google Scholar
• Kassubek J, Muller HP, Del Tredici K, et al. Diffusion tensor imaging analysis of sequential spreading of disease in amyotrophic lateral sclerosis confirms patterns of TDP-43 pathology. Brain. 2014;137:1733–1740.
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Arai K, Del Tredici K, et al. TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathol. 2014;128:423–437.
   PubMed Web of Science ®Google Scholar
• Das S, Zhang Z, Ang LC. Clinicopathological overlap of neurodegenerative diseases: A comprehensive review. J Clin Neurosci. 2020 Aug;78:30–33. DOI:10.1016/j.jocn.2020.04.088. Epub 2020 Apr 27.
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74:20–38.
   PubMed Web of Science ®Google Scholar
• Freibaum BD, Chitta RK, High AA, et al. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J Proteome Res. 2010;9:1104–1120.
   PubMed Web of Science ®Google Scholar
• Boeynaems S, Bogaert E, Van Damme P, Van Den Bosch L. Inside out: the role of nucleocytoplasmic transport in ALS and FTLD. Acta Neuropathol. 2016;132:159–173.
   PubMed Web of Science ®Google Scholar
• Guo L, Kim HJ, Wang H, et al. Nuclear-import receptors reverse aberrant phase transitions of RNA-binding proteins with prion-like domains. Cell. 2018;173:677–92 e20.
   PubMed Web of Science ®Google Scholar
• Molliex A, Temirov J, Lee J, et al. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell. 2015;163:123–133.
   PubMed Web of Science ®Google Scholar
• Shorter J, Taylor JP. Disease mutations in the prion-like domains of hnRNPA1 and hnRNPA2/B1 introduce potent steric zippers that drive excess RNP granule assembly. Rare Dis. 2013;1:e25200.
   PubMedGoogle Scholar
• McAlary L, Plotkin SS, Yerbury JJ, et al. Prion-like propagation of protein misfolding and aggregation in amyotrophic lateral sclerosis. Front Mol Neurosci. 2019;12:262.
   PubMed Web of Science ®Google Scholar
• Ludolph AC, Brettschneider J. TDP-43 in amyotrophic lateral sclerosis - is it a prion disease? Eur J Neurol. 2015;22:753–761.
   PubMed Web of Science ®Google Scholar
• Meisl G, Knowles TP, Klenerman D. The molecular processes underpinning prion-like spreading and seed amplification in protein aggregation. Curr Opin Neurobiol. 2020;61:58–64.
   PubMed Web of Science ®Google Scholar
• Brunello CA, Merezhko M, Uronen RL, et al. Mechanisms of secretion and spreading of pathological tau protein. Cell Mol Life Sci. 2020;77:1721–1744.
   PubMed Web of Science ®Google Scholar
• Byrne S, Bede P, Elamin M, et al. Proposed criteria for familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011;12:157–159.
   PubMed Web of Science ®Google Scholar
• Byrne S, Elamin M, Bede P, et al. Absence of consensus in diagnostic criteria for familial neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2012;83:365–367.
   PubMed Web of Science ®Google Scholar
• Byrne S, Hardiman O. Familial aggregation in amyotrophic lateral sclerosis. Ann Neurol. 2010;67:554.
   PubMed Web of Science ®Google Scholar
• Byrne S, Walsh C, Lynch C, et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82:623–627.
   PubMed Web of Science ®Google Scholar
• Mejzini R, Flynn LL, Pitout IL, et al. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. 2019;13:1310.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, van den Berg LH, Veldink J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nat Rev Neurol. 2017;13:96–104.
   PubMed Web of Science ®Google Scholar
• Volk AE, Weishaupt JH, Andersen PM, et al. Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis. Med Genet. 2018;30:252–258.
   PubMedGoogle Scholar
• Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9:617–628.
   PubMed Web of Science ®Google Scholar
• van Rheenen W, Shatunov A, Dekker AM, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet. 2016;48:1043–1048.
   PubMed Web of Science ®Google Scholar
• Tazelaar GHP, Dekker AM, van Vugt J, et al. Association of NIPA1 repeat expansions with amyotrophic lateral sclerosis in a large international cohort. Neurobiol Aging. 2019;74:234 e9- e15.
   Web of Science ®Google Scholar
• Nicolas A, Kenna KP, Renton AE, et al. Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron. 2018;97:1268–83 e6.
   PubMed Web of Science ®Google Scholar
• Kenna KP, van Doormaal PT, Dekker AM, et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat Genet. 2016;48:1037–1042.
   PubMed Web of Science ®Google Scholar
• van Blitterswijk M, van Es MA, Hennekam EA, et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet. 2012;21:3776–3784.
   PubMed Web of Science ®Google Scholar
• Cooper-Knock J, Kirby J, Highley R, et al. The spectrum of C9orf72-mediated neurodegeneration and amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12:326–339.
   PubMed Web of Science ®Google Scholar
• DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245–256.
   PubMed Web of Science ®Google Scholar
• van Es MA, Schelhaas HJ, van Vught PW, et al. Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann Neurol. 2011;70:964–973.
   PubMed Web of Science ®Google Scholar
• Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668–1672.
   PubMed Web of Science ®Google Scholar
• Cannas A, Borghero G, Floris GL, et al. The p.A382T TARDBP gene mutation in Sardinian patients affected by Parkinson’s disease and other degenerative parkinsonisms. Neurogenetics. 2013;14:161–166.
   PubMed Web of Science ®Google Scholar
• Elden AC, Kim HJ, Hart MP, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069–1075.
   PubMed Web of Science ®Google Scholar
• Kim JM, Hong S, Kim GP, et al. Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism. Arch Neurol. 2007;64:1510–1518.
   PubMedGoogle Scholar
• Merner ND, Girard SL, Catoire H, et al. Exome sequencing identifies FUS mutations as a cause of essential tremor. Am J Hum Genet. 2012;91:313–319.
   PubMed Web of Science ®Google Scholar
• Vance C, Rogelj B, Hortobagyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208–1211.
   PubMed Web of Science ®Google Scholar
• Taylor JP. Multisystem proteinopathy: intersecting genetics in muscle, bone, and brain degeneration. Neurology. 2015;85:658–660.
   PubMed Web of Science ®Google Scholar
• Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59–62.
   PubMed Web of Science ®Google Scholar
• Yang Y, Hentati A, Deng HX, et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet. 2001;29:160–165.
   PubMed Web of Science ®Google Scholar
• Chen YZ, Bennett CL, Huynh HM, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet. 2004;74:1128–1135.
   PubMed Web of Science ®Google Scholar
• Daoud H, Zhou S, Noreau A, et al. Exome sequencing reveals SPG11 mutations causing juvenile ALS. Neurobiol Aging. 2012;33(839):e5–9.
   Google Scholar
• Nishimura AL, Mitne-Neto M, Silva HC, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet. 2004;75:822–831.
   PubMed Web of Science ®Google Scholar
• Greenway MJ, Andersen PM, Russ C, et al. ANG mutations segregate with familial and ‘sporadic’ amyotrophic lateral sclerosis. Nat Genet. 2006;38:411–413.
   PubMed Web of Science ®Google Scholar
• Chow CY, Landers JE, Bergren SK, et al. Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. Am J Hum Genet. 2009;84:85–88.
   PubMed Web of Science ®Google Scholar
• Hortobagyi T, Troakes C, Nishimura AL, et al. Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders. Acta Neuropathol. 2011;121:519–527.
   PubMed Web of Science ®Google Scholar
• Johnson JO, Mandrioli J, Benatar M, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68:857–864.
   PubMed Web of Science ®Google Scholar
• Deng HX, Chen W, Hong ST, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011;477:211–215.
   PubMed Web of Science ®Google Scholar
• Belzil VV, Daoud H, Camu W, et al. Genetic analysis of SIGMAR1 as a cause of familial ALS with dementia. Eur J Hum Genet. 2013;21:237–239.
   PubMed Web of Science ®Google Scholar
• Parkinson N, Ince PG, Smith MO, et al. ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). Neurology. 2006;67:1074–1077.
   PubMed Web of Science ®Google Scholar
• Smith BN, Vance C, Scotter EL, et al. Novel mutations support a role for profilin 1 in the pathogenesis of ALS. Neurobiol Aging. 2015;36(1602):e17–27.
   Google Scholar
• Takahashi Y, Fukuda Y, Yoshimura J, et al. ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19. Am J Hum Genet. 2013;93:900–905.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim NC, Wang YD, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495:467–473.
   PubMed Web of Science ®Google Scholar
• Johnson JO, Pioro EP, Boehringer A, et al. Mutations in the matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosci. 2014;17:664–666.
   PubMed Web of Science ®Google Scholar
• Pensato V, Tiloca C, Corrado L, et al. TUBA4A gene analysis in sporadic amyotrophic lateral sclerosis: identification of novel mutations. J Neurol. 2015;262:1376–1378.
   PubMed Web of Science ®Google Scholar
• Smith BN, Topp SD, Fallini C, et al. Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Sci Transl Med. 2017 May 3;9(388):eaad9157. DOI:10.1126/scitranslmed.aad9157
   Web of Science ®Google Scholar
• Bannwarth S, Ait-El-Mkadem S, Chaussenot A, et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain. 2014;137:2329–2345.
   PubMed Web of Science ®Google Scholar
• Fecto F, Yan J, Vemula SP, et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol. 2011;68:1440–1446.
   PubMed Web of Science ®Google Scholar
• Freischmidt A, Muller K, Ludolph AC, et al. Association of mutations in TBK1 with sporadic and familial amyotrophic lateral sclerosis and frontotemporal dementia. JAMA Neurol. 2017;74:110–113.
   PubMed Web of Science ®Google Scholar
• Cirulli ET, Lasseigne BN, Petrovski S, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347:1436–1441.
   PubMed Web of Science ®Google Scholar
• Conforti FL, Spataro R, Sproviero W, et al. Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis. Neurology. 2012;79:2315–2320.
   PubMed Web of Science ®Google Scholar
• Dadon-Nachum M, Melamed E, Offen D. The “dying-back” phenomenon of motor neurons in ALS. J Mol Neurosci. 2011;43:470–477.
   PubMed Web of Science ®Google Scholar
• Chou SM, Norris FH. Amyotrophic lateral sclerosis: lower motor neuron disease spreading to upper motor neurons. Muscle Nerve. 1993;16:864–869.
   PubMed Web of Science ®Google Scholar
• Abrahams S, Newton J, Niven E, et al. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:9–14.
   PubMed Web of Science ®Google Scholar
• Gosselt IK, Nijboer TCW, Van Es MA. An overview of screening instruments for cognition and behavior in patients with ALS: selecting the appropriate tool for clinical practice. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Mar 11;1–13. DOI:10.1080/21678421.2020.1732424. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Cammack AJ, Atassi N, Hyman T, et al. Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers. Neurology. 2019;93:e1605–e17.
   PubMed Web of Science ®Google Scholar
• Bali T, Self W, Liu J, et al. Defining SOD1 ALS natural history to guide therapeutic clinical trial design. J Neurol Neurosurg Psychiatry. 2017;88:99–105.
   PubMed Web of Science ®Google Scholar
• Todd TW, Petrucelli L. Insights into the pathogenic mechanisms of chromosome 9 open reading frame 72 (C9orf72) repeat expansions. J Neurochem. 2016;138(Suppl 1):145–162.
   PubMedGoogle Scholar
• Li Q, Vande Velde C, Israelson A, et al. ALS-linked mutant superoxide dismutase 1 (SOD1) alters mitochondrial protein composition and decreases protein import. Proc Natl Acad Sci U S A. 2010;107:21146–21151.
   PubMed Web of Science ®Google Scholar
• Berk JL, Barroso FA, Coelho T. Oligonucleotide drugs for transthyretin amyloidosis. N Engl J Med. 2018;379:2085–2086.
   PubMedGoogle Scholar
• Bishop KM, Montes J, Finkel RS. Motor milestone assessment of infants with spinal muscular atrophy using the hammersmith infant neurological exam-part 2: experience from a nusinersen clinical study. Muscle Nerve. 2018;57:142–146.
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, et al. Targeting huntingtin expression in patients with huntington’s disease. N Engl J Med. 2019;380:2307–2316.
   PubMed Web of Science ®Google Scholar
• Park JJH, Hsu G, Siden EG, et al. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin. 2020;70:125–137.
   PubMed Web of Science ®Google Scholar
• Zaman A, Wu W, Bivona TG. Targeting oncogenic BRAF: past, present, and future. Cancers (Basel). Pharmacogenomics J. 2020 Apr;20(2):220–226. DOI:10.1038/s41397-019-0111-3. Epub 2019 Oct 17.
   Web of Science ®Google Scholar
• van Eijk RPA, Eijkemans MJC, Nikolakopoulos S, et al. Pharmacogenetic interactions in amyotrophic lateral sclerosis: a step closer to a cure? Pharmacogenomics J. 2020;20:220–226.
   PubMed Web of Science ®Google Scholar
• van Eijk RPA, Jones AR, Sproviero W, et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology. 2017;89:1915–1922.
   PubMed Web of Science ®Google Scholar
• Li W, Lee MH, Henderson L, et al. Human endogenous retrovirus-K contributes to motor neuron disease. Sci Transl Med. 2015;7:307ra153.
   PubMed Web of Science ®Google Scholar
• Gold J, Rowe DB, Kiernan MC, et al. Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the lighthouse trial. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:595–604.
   PubMed Web of Science ®Google Scholar